Diovan news from FiercePharma
News
Profits rise at Novartis, Merck, Lilly
Good financial results from three Pharma biggies should cheer up those market-watchers who moaned their way through much of last week. Sure, a couple of the profit leaps came at least in part from Read more...
ALSO NOTED: Biovail, Watson settle Cardizem patent fight; More Novartis/Bayer rumors;
> In settlement of a patent dispute, Watson Pharmaceuticals agreed to delay its launch of a generic version of Biovail's Cardizem blood pressure drug, and to pay royalties on sales after that. Read more...
SPOTLIGHT: FDA gives nod to Ranbaxy's generic Diovan
India's Ranbaxy Laboratories got a tentative FDA OK for a generic version of the Novartis drug Diovan, used to treat high blood pressure and heart failure. Read more...
Rasilez approval spurs Novartis expansion
Bolstered by the EU's blessing on its new hypertension treatment Rasilez, Novartis is planning a €183 million ($250 million) expansion of a plant near Basel, Switzerland. The expansion will boost Read more...
Novartis, Ranbaxy argue over Diovan patent
Meanwhile, Novartis is suing the Indian generics giant Ranbaxy Laboratories over a copycat version of Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight